Humalog (Insulin Lispro)

Insulin Lispro (brand name Humalog) is a rapid-acting insulin analogue and was, in the mid-1990s, the first genetically engineered insulin analogue ever to receive approval. The change to the molecule is tiny: in the B chain the amino acids at positions 28 and 29 are swapped. The natural proline-lysine sequence becomes lysine-proline, hence the name Lis-Pro.

That single swap changes nothing about the action at the receptor, but everything about the timing. It is the reason lispro starts working after 15 minutes instead of the 30 to 45 of regular human insulin.

This information is for research and educational purposes only. No medical advice.

Insulin in solution does not sit as a single molecule but self-associates into dimers and hexamers. Only the monomer, however, can cross from the subcutaneous depot into the bloodstream. With human insulin the hexamer assembly has to break apart first. That dissociation is the bottleneck.

The swap at B28 and B29 weakens exactly the contact surfaces the molecules use to stick together. Lispro dissociates into monomers faster and is absorbed correspondingly earlier.

At the insulin receptor itself, lispro then behaves like the body's own insulin:

• Receptor tyrosine kinase: is activated and starts the signalling cascade.
• GLUT4 transporters: move to the cell membrane, glucose uptake into muscle and fat tissue rises.
• Liver: hepatic glucose output is throttled.
• Fat tissue: lipolysis is inhibited, storage is promoted.
• Potassium: the sodium-potassium ATPase pushes potassium from the blood into the cell - serum potassium falls.

The timing profile is the entire point of this substance and at the same time its danger:

• Onset: around 15 minutes after subcutaneous administration.
• Serum peak: about 30 to 70 minutes.
• Maximum effect: 1 to 2 hours.
• Duration: 3 to 5 hours.
• Half-life: about 1 hour after subcutaneous injection.
• Bioavailability: roughly 55 to 77 percent in the approval data.

For comparison, regular human insulin needs 30 to 45 minutes to take effect and keeps acting for 6 to 8 hours. That long tail is the classic reason for late hypoglycemia. Lispro solves that problem and creates a new one: the action window is so tight that delayed or skipped carbohydrate intake leads straight into hypoglycemia at the peak.

Insulin is the one substance class in the catalogue where a dosing error can end fatally within one to two hours. That is not cautious phrasing, it is the plain description of the mechanism.

Early warning signs: tremor, cold sweat, racing heartbeat, pallor, ravenous hunger, inner restlessness.

Later: impaired concentration and vision, slurred speech, confused or aggressive behaviour.

At the end: seizure, unconsciousness, death.

• Fast carbohydrates (glucose tablets, juice, soft drink) must be within reach before the needle goes in, not afterwards. For emergencies, glucagon belongs alongside them.
• Never use alone. A person present has to know what to do in a hypoglycemic event.
• Never without a blood glucose meter. Dosing by feel does not work with this substance.
• After repeated hypoglycemic events the warning symptoms blunt. The first noticed stage is then already confusion.
• Alcohol, beta blockers and physical exertion amplify the glucose drop while masking the symptoms.

A second, frequently overlooked point: the potassium shift. Insulin drives potassium into cells and serum potassium falls. The effect is so reliable that insulin is used clinically on purpose to lower elevated potassium. Relevant hypokalemia causes muscle weakness, cramps and cardiac arrhythmia - at high doses it is an independent cause of death, entirely separate from blood glucose.

The evidence base on lispro is old, large and unusually clear-cut.

• Howey et al., Diabetes 1994: in glucose clamp work the serum insulin peak after lispro was more than twice as high and was reached in less than half the time compared to regular human insulin. That is the pharmacokinetic proof of the amino acid swap.
• Anderson et al., Diabetes 1997: multicenter crossover trial with 1,008 participants over six months. Significantly flatter postprandial glucose rise and around 12 percent fewer hypoglycemic episodes versus regular human insulin, with the largest relative advantage at night.
• Brunelle et al., Diabetes Care 1998: meta-analysis across eight trials and more than 1,400 patient-years. Severe hypoglycemia occurred in 3.1 percent of participants on lispro versus 4.4 percent on regular human insulin.
• Howey et al., Clin Pharmacol Ther 1995: on injection timing. Equal or slightly better control at an average 22.5 minutes before the meal versus 63.8 minutes for regular human insulin.
• Ebeling et al., Diabetes Care 1997: the most important contextual finding. The advantage of a fast bolus insulin evaporates if basal coverage does not match it. Lispro does not replace basal insulin, it complements it.

• Hypoglycemia: by far the most frequent and most dangerous documented adverse effect, a direct consequence of the mechanism.
• Hypokalemia: from the intracellular potassium shift, with muscle weakness, cramps and cardiac arrhythmia.
• Lipohypertrophy and lipoatrophy: tissue changes at frequently used injection sites. Hardened areas absorb unpredictably, which can both blunt the effect and unexpectedly accelerate it. Systematic site rotation is standard in every protocol.
• Local reactions: redness, itching and swelling at the injection site.
• Weight gain: belongs to the known profile of any insulin therapy.
• Edema: sodium retention with peripheral edema is documented particularly at the start.
• Risk of mix-up: insulins differ in concentration (U-100 versus U-200 and higher) and in action profile. A U-100 syringe used with a more concentrated solution delivers a multiple of the intended dose. Check type and concentration before every administration.

Store unopened refrigerated at 2 to 8 degrees. Do not freeze - frozen insulin is unusable, even after thawing. Once in use, keep at room temperature below 30 degrees, protected from light and direct heat.

The solution has to be clear and colourless. Cloudiness, flakes, discolouration or precipitates mean: do not use it any more. Keep out of reach of children.